Galectin Therapeutics INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Richard E. Uihlein has significantly increased his beneficial ownership in Galectin Therapeutics Inc. to 49.3% through debt conversion, raising questions about control and future strategy.